Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Datopotamab deruxtecan
Related studies linked through entity extraction aliases.
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- Status
- RECRUITING
- Phase
- PHASE2
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- Status
- RECRUITING
- Phase
- PHASE2
Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Status
- RECRUITING
- Phase
- PHASE2
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Status
- RECRUITING
- Phase
- PHASE2
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2